Table 3.

Clinical Trials Targeting Inflammation For Cancer Prevention.

AGENT	TARGET	RESULT	REFERENCE
Sulindac	FAP polyp regression	↓polyps	Giardiello 1993
Sulindac	FAP new polyp development	no effect	Giardiello 2002 [135]
Celecoxib	FAP polyp regression	↓polyps	Steinbach 2000 [136]
Celecoxib	sporadic colorectal polyp recurrence	↓polyps	Bertagnolli 2006 [139]
Rofecoxib	sporadic colorectal polyp recurrence	↓polyps	Arber 2006 [140] Baron 2006 [141]
Aspirin	sporadic colorectal polyp recurrence	↓polyps	Baron 2003 Sandler 2003 [138]
Sulindac + DFMO	sporadic colorectal polyp recurrence	↓polyps	Meyskens 2008 [147]
Celecoxib	Barrett's esophagus	no effect	Heath 2007 [142]
Celecoxib	oral leukoplakia	no effect	Papadimitrakopoulou 2008 [144]
Ketorolac	oral leukoplakia	no effect	Mulshine 2004 [143]
Budesonide	bronchial dysplasia	no effect	Lam 2004 [145]

FAP=familial adenomatous polyposis